drugset
drugset / Trial / NCT00268918

Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients

NCT00268918 ↗

Phase 1 Completed 24 enrolled Dana-Farber Cancer Institute Brigham and Women's Hospital · collabMassachusetts General Hospital · collab
NaSingle-groupOpen-labelTreatment

Summary

The main purpose of this study is to see if the study drug, PTK787, is safe and to find the highest dose that can be given safely without causing serious side effects.

Timeline

Start
2005-09
Primary completion
2007-01
Completion
2011-01

Drugs

EvaluationDrugModalityDoseRoute
Subject vatalanib Small molecule — Oral
Background Docetaxel Small molecule — Intravenous

Indications

breast cancer cervical cancer endometrial cancer fallopian tube cancer ovarian cancer peritoneum cancer